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Rapid quantitative assays for glucose-6-phosphate
dehydrogenase (G6PD) and hemoglobin combined
on a capillary-driven microfluidic chip†
Marco Rocca, ab Yuksel Temiz, a Marie L. Salva,ab Samuel Castonguay,c
Thomas Gervais, cde Christof M. Niemeyer b and Emmanuel Delamarche*a
Rapid tests for glucose-6-phosphate dehydrogenase (G6PD) are extremely important for determining
G6PD deficiency, a widespread metabolic disorder which triggers hemolytic anemia in response to
primaquine and tafenoquine medication, the most effective drugs for the radical cure of malaria caused by
Plasmodium parasites. Current point-of-care diagnostic devices for G6PD are either qualitative, do not
normalize G6PD activity to the hemoglobin concentration, or are very expensive. In this work we
developed a capillary-driven microfluidic chip to perform a quantitative G6PD test and a hemoglobin
measurement within 2 minutes and using less than 2 μL of sample. We used a powerful microfluidic
module to integrate and resuspend locally the reagents needed for the G6PD assay and controls. We also
developed a theoretical model that successfully predicts the enzymatic reactions on-chip, guides on-chip
reagent spotting and allows efficient integration of multiple assays in miniaturized formats with only a few
nanograms of reagents.
Introduction
This work relates to portable tests for assessing glucose-6-
phosphate dehydrogenase (G6PD) deficiency using capillary-
driven microfluidic chips. G6PD deficiency is an inherited
metabolic disorder of red blood cells (RBCs) affecting more
than 400 million people worldwide, mostly in Africa and
South Asia.1–4 The spatial geographic distribution of G6PD
deficiency consistently overlaps with regions where malaria is
endemic,5 and there is strong evidence that G6PD mutations
are associated with a lower risk of severe malaria.6,7
Primaquine and the more recent drug tafenoquine are the
most preferred drugs for the radical curative treatment of
malaria caused by the parasites Plasmodium vivax and
Plasmodium ovale. However, as for other 8-aminoquinoline-
based drugs, both medications can trigger hemolytic anemia
in people with G6PD deficiency.8–10 Hence, testing for G6PD
deficiency before deciding which anti-malaria drug to
administer can save the life of people affected by malaria.11,12
Being a chromosome X-linked genetic trait, G6PD deficiency
causes two discrete ranges of G6PD activities in males
(deficient, not deficient), but also an intermediate activity
range in females, making it difficult to be identified with a
qualitative rapid test.10,13
There are two main classes of assays for determining the
G6PD status of individuals: genetic assays, which are more
suitable for population studies, and phenotypic assays, which
are used for making rapid clinical decisions. Most genetic
assays employ PCR-based single-nucleotide polymorphism
(SNP) analysis.4 However, PCR-SNP analysis only identifies the
presence or absence of known genotypes, and therefore it
may not identify G6PD deficiency in patients with mutations,
which are not included in the reference panel.14 Alternatively,
DNA sequencing methods are able to identify all the
mutations occurring on the G6PD gene; however, any new
mutation identified should be characterized with a
phenotypic assay first to determine if it is related with a
decrease in the enzymatic activity of G6PD.4 To date, 253
different genetic mutations of the G6PD gene are known.15,16
According to the most recent WHO classification of the
variants of the G6PD gene, at least 145 mutations are related
to a decrease in the phenotypic activity of G6DP.17,18 Genetic
assays are a useful method for population studies because
such tests do not require intact enzymatic activity and become
cheaper when performed on a larger scale. However, genetic
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assays are expensive to perform on request, require an
equipped laboratory with trained personnel and are not
suitable for rapid on-site estimation of the risk associated
with G6PD deficiency.
Phenotypic assays are able to determine the activity of G6PD
in RBCs and therefore can help physicians in taking fast clinical
decisions. Originally, phenotypic assays were only available in
newborn-screening facilities and central laboratories. Now,
several point-of-care (POC) devices are available on the market
and G6PD assays can be performed directly in the field.
Phenotypic assays can be classified into three main groups: (i)
qualitative assays, (ii) cytochemical assays and (iii) quantitative
assays. Qualitative assays only provide a base result of deficient/
not deficient and usually diagnose as G6PD-deficient all
patients having G6PD activity less than 30% of the normal
activity.4 In general, these tests are based on a colorimetric/
fluorometric assay, cheap and easy to perform and require only
minimal laboratory equipment. The gold standard G6PD assay
for a qualitative readout is the fluorescent spot test. It was first
established by E. Beutler in the 1960s and relies on the
detection of NADPH produced in a dried blood spot mixed with
G6P and NADP+. The test readout is obtained using UV light
(365 nm).19,20 Brewer et al. developed the methemoglobin
reduction test, which relies on the oxidation of hemoglobin to
methemoglobin and the subsequent enzymatic reconversion to
hemoglobin by TPNH-methemoglobin reductase in the
presence of NADPH.21 To date, most of the qualitative assays
known in the literature or available on the market are based on
a colorimetric assay, including formazan-based methods using
either the substrate 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H
tetrazolium bromide (MTT) and a hydrogen carrier such as
phenazine methosulfate or the substrate 2-(2-methoxy-4-
nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H
tetrazoliummonosodium salt (WST-8).22–26 However, qualitative
assays are limited in performance since they are not able to
distinguish G6PD deficiency in females with an intermediate
G6PD activity ranging from ∼30% to 80%.27
Cytochemical assays look at the individual activity of
G6PD over a large population of cells and therefore are suited
to determine intermediate G6PD deficiency by statistics. In
1968, Fairbanks and Lampe introduced a cytochemical assay
based on the reduction of MTT into insoluble tetrazolium
salts, which is related to the G6PD activity in RBCs.28 Another
cytochemical assay was introduced in 1982 by Van Noorden
et al., where the G6PD activity of individual RBCs was
analyzed indirectly using the dose-dependent quenching of
the autofluorescence of glutaraldehyde by formazan,
generated by the activity of G6PD.29,30 Shah et al. proposed a
novel cytofluorometric assay to measure G6PD-deficient RBCs
through a sequential reaction of cyanide followed by peroxide
to generate a fluorescent product (ferryl-Hb) inside RBCs.31
Cytochemical assays provide the most accurate method for
determining G6PD deficiency,32 but these assays are
expensive, technically challenging and require laboratory
equipment, which makes them not suited for
implementation on POC diagnostic devices.33,34
Quantitative biochemical assays can measure intermediate
levels of G6PD activities and therefore can be used as a
universal diagnostic tool for detecting G6PD deficiency also
in female subjects. The gold standard for quantitative
determination of G6PD activity relies on spectrophotometry,
which measures the generation of NADPH by G6PD through
an absorbance measurement at 340 nm taken over time. This
assay requires 10 μL of blood and takes about 15–20 minutes
to be performed.10,35 However, this method requires a kinetic
and temperature-controlled spectrophotometer, trained
personnel and a well-equipped laboratory. As an alternative,
several groups are working on modifying existing personal
glucose meters (PGMs) to detect other non-glucose targets.
Antibodies, aptamers, or DNA, for example, are coupled to
enzymes, such as invertase or glucoamylase, which can
convert sugars invisible to the PGM to glucose that is
detectable by the PGM. In particular, Zhang et al. investigated
the linear response of PGMs to varying concentrations of
NADH.36 The same idea can be expanded to measure NADPH
as a product from the oxidation of G6P to 6PGL by the
activity of G6PD.37 However, using a PGM to measure a non-
glucose target suffers from an intrinsic interference from
glucose present in blood, which has to be minimized, for
example, by introducing additional enzymes. Moreover, since
multiple enzymes are employed in this system, the activity of
each enzyme must be carefully calibrated. Yu et al. developed
an alternative sensor for measuring NADPH:38 in the
presence of NADPH, a ligand binds to a receptor and brings
a fluorophore close to a NanoLuc luciferase. This leads to
increased bioluminescence resonance energy transfer, which
is monitored using a digital camera. Such an assay may
suffer from interference by endogenous or exogenous
substances, such as variations in the concentration of
NADPH in blood, inhibitors of luciferase activity, and binding
of substances to the sensor (e.g., the antibiotic
trimethoprim). A quantitative G6PD assay was also
implemented on a digital microfluidic platform, where small
droplets can be moved, merged and split arbitrarily using
electrowetting phenomena, as explained in detail by Sista
et al.39 The fact that this microfluidic droplet assay was
released as a commercial product in 2019 by Baebies, Inc.
underlines the acute and urgent demand for new quantitative
G6PD tests. The droplet platform, however, requires a
laborious chip design and fabrication and an electronic
peripheral to control the motion of droplets, which might
increase the overall cost of the device. Hence, while this
device could be a promising solution for newborn screening
programs, it might not be affordable to be used as a POC
diagnostic device in developing countries.
Phenotypic quantitative biochemical assays are the most
promising assay format to be used as a portable diagnostic
tool to determine G6PD deficiency. However, a measurement
of the activity of G6PD alone, even if very accurate, may be
misleading: G6PD is contained in the RBCs, and therefore it
is necessary to normalize the activity of G6PD to the number
of RBCs to take into account variations in the number of
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RBCs among different blood samples (e.g., to avoid false
positives for anemic people). Standard methods for counting
RBCs use a hemocytometer or an automated cell counter40 or
else the number of RBCs can also be estimated by measuring
the hematocrit and hemoglobin concentrations. A well-suited
method for portable diagnostics is the measurement of
hemoglobin concentration because it can be performed
without bulky equipment and is inexpensive. The most often
used methods for this are the hemoglobincyanide assay, the
azide-methemoglobin assay, the sodium lauryl sulphate assay
and CO-oximetry.41 Other methods are available and were
compared by Srivastava et al.42 An interesting alternative is to
measure the absorbance of blood at one of its isosbestic
points, where the oxidized and non-oxidized state of
hemoglobin, which are the most abundant forms of
hemoglobin present in blood, have the same extinction
coefficient.43 This method does not require additional
reactions to convert hemoglobin to a stable colored form,
avoids the use of hazardous reagents and can be performed
faster than conventional methods (<10 s).
Currently, available POC diagnostic tests for measuring
G6PD activity are either qualitative, do not normalize the
enzyme activity by the concentration of hemoglobin, or are
very expensive.44 Indeed, it is traditionally difficult to
combine two classes of assays on a single device.45 Here, we
exploit capillary phenomena to control the flow of the sample
inside a microfluidic chip to assess G6PD deficiency. A
capillary-driven microfluidic chip is a powerful platform,
which allows working with just a few microliters of sample
and does not require active pumping to move the liquids. We
designed multiple flow paths to accommodate the
requirements of the hemoglobin measurement and
enzymatic assay on a single chip. We used a self-coalescence
module (SCM), a simple yet powerful microfluidic element
recently developed by our group, for homogenously
resuspending reagents in well-defined areas of a
microchannel46 to perform a quantitative G6PD test and
vicinal positive and negative controls simultaneously on the
same chip. We also developed a theoretical model to guide
the integration of assay reagents in the SCM by inkjet
spotting and to predict their dissolution, diffusion and
resulting enzymatic reactions, which generate a fluorescent
reporter of G6PD activity.
Results and discussion
Assay workflow and microfluidic chip layout
Fig. 1a depicts the workflow we used to combine a G6PD and
a hemoglobin assay on a single chip. RBCs from a whole
blood sample are lysed chemically using 10 mM Triton X-100,
a mild surfactant, to avoid denaturation of proteins in the
sample (see ESI† Fig. S1). The concentration of hemoglobin
is measured directly from the lysate by an absorbance
measurement through a transparent chip at the Hb/HbO2
isosbestic point of 530 nm. It is a common practice to use a
diluted sample to perform a G6PD assay to minimize the
interference from other molecules present in blood.44
Available POC tests for G6PD deficiency use dilution factors
ranging from 8 to 301. In this work, we used a 30-fold
dilution, which gives enough dynamic range to distinguish
between a G6PD-spiked sample and a control without G6PD
(see ESI† Fig. S2). Fig. 1b shows the enzymatic reactions we
Fig. 1 Workflow of an assay for determining G6PD activity and hemoglobin concentration in whole blood samples. (a) Lysis of red blood cells
releases hemoglobin and G6PD analytes. The lysate is loaded onto a first loading pad of a microfluidic chip to measure the concentration of
hemoglobin (absorbance measurement). The remaining lysate is diluted with 20 mM Tris buffer and loaded onto a second loading pad of the
microfluidic chip for the G6PD assay (fluorescence measurement). (b) G6PD activity is determined using a coupled enzymatic reaction via the
reduction of resazurin to the fluorescent product resorufin.
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used in the assay to link the activity of G6PD to the
generation of a fluorescent product. G6PD reduces NADP+ to
NADPH, and a second enzyme, diaphorase, oxidizes NADPH
back to NADP+ while reducing resazurin to the fluorescent
product resorufin.
The microfluidic chip has two independent flow paths for
the hemoglobin concentration measurement and the G6PD
assay (Fig. 2a). For the hemoglobin measurement, the lysed
blood sample fills a capillary pump with a predefined volume
and an absorbance measurement is performed through the
chip. The chip is fabricated on a glass substrate, which is
transparent in the wavelength needed to perform the
hemoglobin measurement. The layout of the micropillars in
the pump ensures a steady filling of the capillary pump and
avoids trapping air bubbles,47 which may otherwise affect the
absorbance measurement (see Fig. 2b and ESI† Movie S1). After
the capillary pump, an area having “spots” of inkjet-deposited
dyes provides a labile security code area48 (see ESI† Fig. S3),
which can be used to protect the tests from counterfeiting and
reuse. The reagents for the G6PD assay are integrated into the
SCM by spotting two solutions using an alternating pattern
(see Fig. 2b). One solution contains the substrates and the
cofactors for both enzymes, and the other the section
“Experimental”). The reagents are allowed to dry within a few
seconds after spotting and the microfluidic chips are
sealed.47,49 During an assay, the sample fills the SCM following
a specific trajectory that prevents adverse accumulation of
reagents and greatly minimizes gradients and dispersion of the
reagents due to Taylor–Aris dispersion46 (see ESI† Movie S2).
The flow is driven completely by capillarity and controlled by
microfluidic structures previously developed by our group.50–53
G6PD assay and measurement of hemoglobin concentration
We tested the performance of the G6PD assay using a diluted
blood sample spiked with different concentrations of G6PD.
Fig. 3a shows the kinetics of the enzymatic assay performed
in a microfluidic chip. The assay response was characterized
by plotting the slope of the assay kinetics in the linear part of
the progress curve against the concentration of G6PD. This is
a well-accepted method to measure the activity of
enzymes54,55 and allowed us to obtain a quantitative result in
less than 1 minute. The assay response is linear over a wide
G6PD concentration range (inset in Fig. 3a). Whole blood
contains the enzyme 6-phosphogluconate dehydrogenase,
which is an additional source of NADPH generation in the
pentose phosphate pathway and would increase the
generation of the fluorescent product by the enzyme
diaphorase. To avoid interference in the assay, 26 mM
maleimide was introduced as an inhibitor for the enzyme
6-phosphogluconate dehydrogenase.39,56
The concentration of hemoglobin is measured using an
absorbance measurement through the transparent chip. The
channel height of the chip defines the path length of light
through the sample. In order to obtain a signal, which can be
easily measured with standard readers (0.1–1 OD), a suitable
value for the channel height was estimated using the Beer–
Lambert law. Taking two hemoglobin concentrations covering
the low range (7 g dL−1, for severe anemia57) and the high range
(18 g dL−1, high hemoglobin value58), and the extinction
coefficient of hemoglobin at 530 nm (40000 cm−1 M−1 (ref. 43)),
revealed that a channel height between 23 μm and 89 μm
would be suitable to measure the concentration of hemoglobin
by absorbance. We chose to fabricate the chips with a channel
height of 50 μm. The hemoglobin concentration measurement
was calibrated using a hemoglobin dilution line ranging from
21 g dL−1 down to 3 g dL−1 (Fig. 3b).
Modelling and simulations for multiplexing assays in an
SCM
An SCM provides outstanding flexibility for integrating
multiple assays on the same chip simply by modifying the
spotting pattern of the integrated reagents without changing
Fig. 2 Microfluidic chip for G6PD assay and hemoglobin
concentration determination. (a) 3D render of the microfluidic chip
and (b) photograph of the chip microfabricated in glass after
integration of reagents for G6PD assays and dyes for the security code
using a non-contact piezo-dispensing robot. Micrographs showing
details of (i) reagents spotted in the SCM, (ii) the entrance of the SCM,
and (iii) micropillars forming a capillary active area for hemoglobin
measurement.
























































































Lab Chip, 2021, 21, 3573–3582 | 3577This journal is © The Royal Society of Chemistry 2021
the chip design, which is laborious and expensive. To
perform multiple assays in a single SCM with an economy of
footprint and using small volumes of samples, the
corresponding test zones need to be spaced close to each
other while avoiding interference between the assays. The
appropriate distance between the reagents for different
assays depends mainly on the assay kinetics, the diffusivity
of the reagents involved in the reaction and the assay time.
The spotting pattern of the reagents can be optimized by a
trial-and-error approach. However, being able to model the
assays based on the spotting pattern of the reactants can save
time, generalize the method, and make it deterministic. For
these reasons, we implemented a theoretical model for
predicting the generation of resorufin as a function of
G6PD activity and used finite differences (1D in space) to
solve numerically a set of 10 reaction–diffusion partial
differential equations involving 10 distinct diffusing species
and 8 reaction constants (a detailed description of the
theoretical model is available in the ESI†). The model
accurately predicts the generation of resorufin over time,
including the linear regime and saturation of the reaction
at longer times (see ESI† Fig. S4 and S5). All parameters
were obtained from the literature, except a single one, the
Michaelis–Menten constant KM for the conversion of
resazurin by diaphorase, which, to the best of our
knowledge, is absent from the literature. A single parameter
fit nevertheless enabled us to determine it indirectly using
our experimental data and to yield an accurate description
of the measured production of resorufin (see Fig. 4a).
Simulations revealed that with a spacing between the test
zones of different assays of 1.8 mm, the fluorescence signal
of neighbouring assays overlaps by just 1.23% (>3σ for a
Gaussian fit) after 4 minutes (Fig. 4b), which represents 4
times the duration needed for the assay (G6PD assays were
achieved in <1 min even for the lower concentration
ranges). This spotting pattern allows multiplexing three
assays in less than 7 mm2 of chip area. Fig. 4c is a sketch
of the spotting pattern used to perform three assays
simultaneously in the same SCM, a G6PD test together with
a negative and a positive control. The negative control is
implemented by co-spotting MgSO4, as an inhibitor for
G6PD, together with the reagents needed for the G6PD
assay. The positive control is performed by co-spotting
G6PD together with diaphorase.
Calibration of the G6PD assay to determine G6PD deficiency
We calibrated the G6PD assay to determine G6PD deficiency
using three commercially available reference controls
exhibiting normal, intermediate, and deficient G6PD activity,
which cover a range of G6PD concentrations from 10 up to
106 U dL−1. The G6PD assay and the measurement of
hemoglobin concentration are performed on the same chip
and are compared with the values of G6PD activity and
hemoglobin concentration provided by the vendor of the
reference controls. Fig. 5a shows that we can distinguish the
activity of G6PD between the normal, intermediate and
deficient samples and that the response of the assay is linear
in the clinically relevant dynamic range with an analytical
sensitivity of 0.26 (RFU s−1)/(U dL−1). The concentration of
hemoglobin could be correctly assessed with an error margin
compared to the reference value of 12.6%, 10.6% and 4.9%
for the deficient, intermediate and normal samples
respectively (Fig. 5b). These variations lie within the error
range produced by fabrication variability in the depth of the
microfluidic channels at different positions on a wafer and
between different wafers (see ESI† Fig. S6). Automatization in
the fabrication process would likely yield a more accurate
result for the absorbance measurement.
Fig. 3 Determination of the G6PD activity and hemoglobin
concentration in lysed blood samples using a microfluidic chip. (a)
Fluorescence enzymatic assay using resorufin as a signal reporting
molecule (λex = 550 nm, λem = 585 nm) after diluting and spiking lysed
blood with known concentrations of G6PD. The inset shows the slope
of the kinetic curves in the linear range plotted versus the G6PD
concentration. (b) Absorbance measurements (λ = 530 nm) of
hemoglobin in the lysed blood samples. The error bars in all graphs
represent the standard error of the mean.
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A positive and a negative control test are performed
simultaneously with the G6PD assay (Fig. 5c), using the
spotting pattern shown in Fig. 4c. A high signal in the
positive control validates the test and the signal in the
negative control outputs the background noise. As expected
for any chemical and enzymatic reaction, the activity of G6PD
varies with temperature. Here we introduce an alternative
method to perform a self-calibration of the assay against
temperature variations without the need of additional
heating peripherals and temperature sensors by exploiting
the signal from the positive control. The variation in the
fluorescence signal generation due to temperature between
the G6PD assay and the positive control is constant since it is
the very same assay simply with different concentrations of
G6PD. Therefore, we normalized the signal from the G6PD
test to the positive control, which will provide a value that is
temperature independent. Fig. 5d shows that by normalizing
the signal to the positive control the variations due to
temperature in the range between 25 °C and 37 °C are
limited to 11.8%.
Comparing our method to the “gold standard”
spectrophotometric assay, we note that our test is around 10
times faster (<2 min vs. 20–30 min),59 works with less sample
volume (<2 μL vs. 10–500 μL)59,60 and requires fewer steps
to be performed by the user. Moreover, our test can
measure the concentration of hemoglobin directly on the
same chip, while in the gold standard approach, the
hemoglobin is measured separately. In the next
development iteration of our test, sample preparation steps
such as cell lysis and sample dilution could be integrated
directly on-chip. One method to perform on-chip lysis of
RBCs would be by spotting a surfactant in an additional
SCM upstream and releasing a defined lysate volume using
passive valves. Alternatively, electrodes could be introduced
on-chip to apply a DC or AC electric field and lyse cells by
electroporation.61 This method is faster and free of reagents
but requires electrodes on-chip and a power source and
might generate gas bubbles due to electrolysis. Sample
dilution, which is required for our G6PD assay, could be
integrated on-chip by adding a blister containing the
dilution buffer and a mixing unit. However, since G6PD
deficiency tests are mostly performed by trained
technicians, we believe that including a kit for off-chip
sample dilution is a cheaper and more viable solution and
avoids adding complexity and cost to the test. Finally, a
miniaturized reader able to perform fluorescence and
Fig. 4 Multiplexing assays in an SCM. (a) Comparison between experimental data and numerical simulations for the average production of
resorufin as a function of time and G6PD concentration within a given test zone. The error bars represent the standard error of the mean (n = 9).
Inset: sensitivity curve of the cost function versus the Michaelis–Menten constant for resazurin to diaphorase. (b) Numerical simulations showing
the evolution of the concentration of resorufin over time along the main axis of the SCM (x axis) as a result of initially spotted reagents in three
distinct test zones. (c) Scheme (not to scale) illustrating the spotting pattern of reagents in an SCM for realizing a G6PD test and negative and
positive controls.
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absorbance measurements would need to be developed to
make our test fully portable and affordable at a low price.
Experimental
Chemicals and biochemicals
All reagents were purchased from Sigma-Aldrich unless
otherwise indicated. G6PD calibration controls (normal,
intermediate, deficient) were from Trinity Biotech (Bray,
Ireland). Human serum was purchased from Bioswisstec AB
(Schaffhausen, Switzerland). Whole blood was purchased
from Interregionale Blutspende SRK (Bern, Switzerland).
Microfluidic chip fabrication
Microfluidic chips were fabricated on a 4″ glass wafer
(Planoptik, Elsoff, Germany) using two photolithography
steps in a clean room facility. On each wafer, 40 replicates of
the chip design were fabricated simultaneously. The mask
designs for the lithographic steps were prepared using L-edit
from Mentor Graphics (Oregon, USA). The designs were
patterned on soda lime masks using a direct laser writer
(DWL 2000, Heidelberg Instruments, Heidelberg, Germany).
First, the capillary pinning features were patterned using a 10
μm-thick SU-8 layer, then the microchannel walls were
patterned using a 50 μm-thick SU-8 layer (SU-8 3010 and SU-8
3050, respectively, MicroChem Corp., Massachusetts, USA). At
the end, a thin photoresist (AZ-4562) was deposited
everywhere to protect the microstructures from debris during
the dicing process and then cleaned in acetone followed by
isopropyl alcohol.
Reagent integration on-chip
All stock solutions for the integration of reagents were prepared
using a 20 mM Tris-HCl buffer (pH 7.8) containing 0.2% BSA.
Solutions containing diaphorase and G6PD also contained 3%
trehalose. The reagents were integrated in the SCM using a
non-contact piezo-dispensing robot (Nanoplotter 2.1 GeSiM,
Dresden, Germany) and dried by leaving the solution to
evaporate at room temperature. The reagents needed for the
G6PD assay were integrated using two distinct solutions. A
pattern composed of five spots of solution 1 (0.1 U μL−1
diaphorase) and five spots of solution 2 (200 mM MgCl2, 40
mM G6P, 2 mM NADP+, 26 mM maleimide, and 2 mM
resazurin) were spotted in each of the three test zones of the
SCM (test, negative control, positive control) with a pitch of 600
μm. Each spot was formed by dispensing eight droplets in the
same location (total volume ∼960 pL). The spotting pattern of
solution 2 was shifted by 300 μm along the pattern of solution
1, leading to an alternated spotting pattern. To integrate the
inhibitor used in the negative control area, solution 3 (2 M
MgSO4) was spotted on top of the existing spots of solution 1
and of solution 2 in the negative control test zone, with a pitch
of 300 μm (total volume per spot ∼1.2 nL). To integrate the
reagent needed for the positive control, five spots of solution 4
(5000 μU μL−1 G6PD) were spotted on top of the spots of
solution 1 in the positive control test zone with a pitch of 600
μm (total volume per spot ∼240 pL). The security code was
spotted using solution 5 (3.3 mg mL−1 erioglaucine disodium
salt containing 10% glycerol). The chips were sealed using a
dry film resist (DF-1050, EMS Inc., USA).
Fig. 5 G6PD assay calibration using standard reference samples from Trinity Biotech performed at 30 °C. (a and b) G6PD assays and hemoglobin
measurements performed in parallel on a microfluidic chip. (c) Example of reaction kinetics of a test (reference sample for intermediate G6PD
activity), positive and negative control measured from the same chip. (d) G6PD assays performed at different temperatures and normalized using
the signal value of positive controls. The error bars represent the standard deviation.
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Assay measurement and software
Images of the microfluidic chips were taken using a Nikon 1
J3 camera connected to a Leica MZ16 stereomicroscope, a
slide scanner (VS120, Olympus) or a custom-made
microscope equipped with an 8-megapixel CMOS camera and
controlled by a Raspberry Pi. The fluorescence and
absorbance measurements were performed using a plate
reader (Tecan Infinite 200, Männedorf, Switzerland) equipped
with a custom-made aluminium chip holder (see ESI† Fig.
S7a). A code for evaluating the results and a code for
generating a pseudo-random security code were written in
Python. The program to run numerical simulations was
written in MATLAB.
Conclusions
In this work we implemented a quantitative assay for
measuring the G6PD activity and the hemoglobin
concentration on a single capillary-driven microfluidic chip
and we were able to distinguish between deficient,
intermediate and normal levels of G6PD activities in less
than 1 minute using only 2 μL of sample. This device has
several advantages. First, it is a modular and flexible
platform, which combines two classes of assays into a single
device, namely a hemoglobin concentration measurement
and an enzymatic assay. There are various scenarios, where
knowing the concentration of hemoglobin together with a
diagnostic test can lead to a more accurate diagnosis,4,45,62,63
and this paper showed how this can be useful for G6PD
deficiency. Second, we implemented a theoretical model
based on the diffusion and reaction of the reagents to predict
the generation of the fluorescent reporting molecule for the
G6PD assay starting from spotted reagents in an SCM. The
main innovation of this diffusion–reaction model is to fully
account for the double enzymatic coupling between G6PD
and diaphorase, which interact through the exchange of the
co-factor NADPH and its oxidized form NADP+. This model
can also be used to identify the limiting reagents in the
enzymatic reaction and tune accordingly the initial
concentrations of the reagents to minimize the amount of
reagents required. Such a model is the first of its kind and
we believe it will be used as a template for modelling various
types of enzymatic reactions and optimizing reagent
integration on-chip. Third, this theoretical model provides
guidelines for integrating reagents by means of inkjet
deposition and allows assays to be multiplexed with a high
degree of precision in a very small area of the microfluidic
chip. The flexibility in multiplexing assays provided by the
SCM outperforms traditional lateral flow assays, where only a
single positive control is usually performed together with the
test. In this work we demonstrated the integration of a G6PD
assay, a positive control and a negative control in less than 7
mm2 of chip area. Such an integration is particularly
promising in light of recent developments on integrated, low
cost and compact optical and fluorescence readers for mobile
diagnostics. For these reasons, we envision that the SCM
could be used as a robust and efficient microfluidic platform
to perform a variety of solution-based assays, for example, for
metabolic disorders, therapy monitoring, or for quality
control of drugs in various settings. Fourth, we proposed an
alternative method for calibrating an enzymatic assay against
temperature variations directly on-chip. Temperature
variations can originate, for instance, from ambient
conditions and peripheral devices and will inevitably affect
the enzymatic activity. The most common way to minimize
the effect of temperature on enzymatic assays is by
performing the assay at a constant and predefined
temperature. This requires a temperature-controlled reader
and is usually implemented on clinical analysers in central
laboratories. Alternatively, the assay can be calibrated at
different temperatures and the enzyme activity retrieved by
measuring the ambient temperature. This method, however,
requires an additional temperature sensor and electronic
circuitry to measure the ambient temperature. Here, we
normalized the test signal by the positive control signal and
were able to cancel out variations in the output signal due to
temperature. Such a feature is a smart alternative to avoid
external peripherals and additional electronic circuitry and
we were able to implement it thanks to the versatility of the
SCM.
In summary, this work presents a state-of-the-art
experimental approach for performing enzymatic assays in
an SCM that is guided by a detailed theoretical model for
integrating reagents and predicting the resulting enzymatic
reactions. Evidently, the SCM can play an important role in
the implementation of solution-based assays, which are
performed with very low sample volumes and a limited
quantity of reagents. We therefore believe that this work will
provide a solid basis for the design and implementation of
many types of assays for high-performance point-of-care
testing methods.
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